Drug Guidance for Subsidy 04/06/2025 Teriparatide biosimilar for treating osteoporosis The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sond... See all × 04/06/2025 Teriparatide biosimilar for treating osteoporosis The Ministry of Health’s Drug Advisory Committee has recommended teriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection for treatment of patients with severe established osteoporosis (T-score ≤ -3.0) with a history of ≥ 2 vertebral fractures or ≥ 2 fragility fractures. The maximum lifetime duration of teriparatide treatment should be limited to 24 months. The decision was based on the acceptable pricing proposal from the company. Funding status RTeriparatide biosimilar (Sondelbay) 600 mcg/2.4 mL injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025. NRMAF assistance does not apply to other brand(s), formulation(s) or strengths(s) of teriparatide for treating osteoporosis. 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teripa... See all × 01/06/2023 Romosozumab and teriparatide for treating osteoporosis NRThe Ministry of Health’s Drug Advisory Committee has not recommended: Romosozumab or teriparatide for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and Teriparatide for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
SUBCUTANEOUS Select a brand starting with the letter: S SONDELBAY INJECTION 20 MCG/80 MCL [SIN16802P]